Clinical-stage, small molecule biotechnology company Redx Pharma (JPJ: REDX) announced on Monday that it presented positive Phase 1 trial results for RXC008, a potential first-in-class treatment for fibrostenotic Crohn's disease, at the 20th Congress of the European Crohn's and Colitis Organisation in Berlin.

RXC008, an orally administered pan-ROCK inhibitor designed to remain gut-restricted, was well tolerated across all tested doses, with no safety concerns, serious adverse events, or discontinuations.

The study confirmed that RXC008 achieved predicted efficacious concentrations in gastrointestinal tissue with minimal systemic exposure, avoiding cardiovascular side effects associated with systemic pan-ROCK inhibitors.

A Phase 2 trial is planned for H2 2025.

Redx Pharma focuses on developing targeted small-molecule therapeutics for fibrotic diseases and oncology, with an industry-leading ROCK inhibitor portfolio.